Header Logo

Connection

PETER HOTEZ to Vaccines, Synthetic

Back to Details
This is a "connection" page, showing publications PETER HOTEZ has written about Vaccines, Synthetic.
PETER HOTEZ
Connection Strength
5.272
Vaccines, Synthetic
  1. Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate. J Pharm Sci. 2017 08; 106(8):1961-1970.
    View in: PubMed
    Score: 0.515
  2. The evaluation of recombinant hookworm antigens as vaccines in hamsters (Mesocricetus auratus) challenged with human hookworm, Necator americanus. Exp Parasitol. 2008 Jan; 118(1):32-40.
    View in: PubMed
    Score: 0.259
  3. New technologies for the control of human hookworm infection. Trends Parasitol. 2006 Jul; 22(7):327-31.
    View in: PubMed
    Score: 0.241
  4. Expression of the Necator americanus hookworm larval antigen Na-ASP-2 in Pichia pastoris and purification of the recombinant protein for use in human clinical trials. Vaccine. 2005 Sep 15; 23(39):4754-64.
    View in: PubMed
    Score: 0.230
  5. A Journey in Science: Molecular vaccines for global child health in troubled times of anti-science. Mol Med. 2024 Mar 15; 30(1):37.
    View in: PubMed
    Score: 0.207
  6. Progress in the development of a recombinant vaccine for human hookworm disease: the Human Hookworm Vaccine Initiative. Int J Parasitol. 2003 Sep 30; 33(11):1245-58.
    View in: PubMed
    Score: 0.201
  7. Effect of vaccination with a recombinant fusion protein encoding an astacinlike metalloprotease (MTP-1) secreted by host-stimulated Ancylostoma caninum third-stage infective larvae. J Parasitol. 2003 Aug; 89(4):853-5.
    View in: PubMed
    Score: 0.199
  8. Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice. Front Immunol. 2022; 13:800295.
    View in: PubMed
    Score: 0.179
  9. COVID-19 vaccine decisions: considering the choices and opportunities. Microbes Infect. 2021 May-Jun; 23(4-5):104811.
    View in: PubMed
    Score: 0.169
  10. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. 2020 11 03; 38(47):7533-7541.
    View in: PubMed
    Score: 0.163
  11. Developing a low-cost and accessible COVID-19 vaccine for global health. PLoS Negl Trop Dis. 2020 07; 14(7):e0008548.
    View in: PubMed
    Score: 0.161
  12. Hookworm burden reductions in BALB/c mice vaccinated with recombinant Ancylostoma secreted proteins (ASPs) from Ancylostoma duodenale, Ancylostoma caninum and Necator americanus. Vaccine. 2000 Jan 06; 18(11-12):1096-102.
    View in: PubMed
    Score: 0.155
  13. Antibody-dependent reductions in mouse hookworm burden after vaccination with Ancylostoma caninum secreted protein 1. J Infect Dis. 1999 Nov; 180(5):1674-81.
    View in: PubMed
    Score: 0.153
  14. Experimental approaches to the development of a recombinant hookworm vaccine. Immunol Rev. 1999 Oct; 171:163-71.
    View in: PubMed
    Score: 0.152
  15. Ligand binding properties of two Brugia malayi fatty acid and retinol (FAR) binding proteins and their vaccine efficacies against challenge infection in gerbils. PLoS Negl Trop Dis. 2018 10; 12(10):e0006772.
    View in: PubMed
    Score: 0.142
  16. Progress in the development of a vaccine against schistosomiasis in China. Int J Infect Dis. 1998 Jan-Mar; 2(3):176-80.
    View in: PubMed
    Score: 0.135
  17. Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults. PLoS Negl Trop Dis. 2017 05; 11(5):e0005574.
    View in: PubMed
    Score: 0.129
  18. Vaccination with alum-precipitated recombinant Ancylostoma-secreted protein 1 protects mice against challenge infections with infective hookworm (Ancylostoma caninum) larvae. J Infect Dis. 1996 Dec; 174(6):1380-3.
    View in: PubMed
    Score: 0.125
  19. Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. Hum Vaccin Immunother. 2017 03 04; 13(3):621-633.
    View in: PubMed
    Score: 0.124
  20. Molecular approaches to vaccinating against hookworm disease. Pediatr Res. 1996 Oct; 40(4):515-21.
    View in: PubMed
    Score: 0.124
  21. Expression, purification, and characterization of the Necator americanus aspartic protease-1 (Na-APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine. Hum Vaccin Immunother. 2015; 11(6):1474-88.
    View in: PubMed
    Score: 0.110
  22. The medical biochemistry of poverty and neglect. Mol Med. 2014 Dec 16; 20 Suppl 1:S31-6.
    View in: PubMed
    Score: 0.109
  23. Optimization and revision of the production process of the Necator americanus glutathione S-transferase 1 (Na-GST-1), the lead hookworm vaccine recombinant protein candidate. Hum Vaccin Immunother. 2014; 10(7):1914-25.
    View in: PubMed
    Score: 0.102
  24. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines. 2012 Dec; 11(12):1405-13.
    View in: PubMed
    Score: 0.095
  25. Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths. J Allergy Clin Immunol. 2012 Jul; 130(1):169-76.e6.
    View in: PubMed
    Score: 0.092
  26. A history of hookworm vaccine development. Hum Vaccin. 2011 Nov; 7(11):1234-44.
    View in: PubMed
    Score: 0.088
  27. Potency testing for the experimental Na-GST-1 hookworm vaccine. Expert Rev Vaccines. 2010 Oct; 9(10):1219-30.
    View in: PubMed
    Score: 0.082
  28. Randomized, placebo-controlled, double-blind trial of the Na-ASP-2 hookworm vaccine in unexposed adults. Vaccine. 2008 May 02; 26(19):2408-17.
    View in: PubMed
    Score: 0.068
  29. Hookworm vaccines. Clin Infect Dis. 2008 Jan 15; 46(2):282-8.
    View in: PubMed
    Score: 0.068
  30. Reduction of worm fecundity and canine host blood loss mediates protection against hookworm infection elicited by vaccination with recombinant Ac-16. Clin Vaccine Immunol. 2007 Mar; 14(3):281-7.
    View in: PubMed
    Score: 0.063
  31. The impact of concurrent and treated Ancylostoma ceylanicum hookworm infections on the immunogenicity of a recombinant hookworm vaccine in hamsters. J Infect Dis. 2006 Jan 01; 193(1):155-62.
    View in: PubMed
    Score: 0.058
  32. Effect of combining the larval antigens Ancylostoma secreted protein 2 (ASP-2) and metalloprotease 1 (MTP-1) in protecting hamsters against hookworm infection and disease caused by Ancylostoma ceylanicum. Vaccine. 2005 May 02; 23(24):3123-30.
    View in: PubMed
    Score: 0.056
  33. Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-na?ve adults. PLoS Negl Trop Dis. 2024 Dec; 18(12):e0012788.
    View in: PubMed
    Score: 0.055
  34. Vaccination of dogs with a recombinant cysteine protease from the intestine of canine hookworms diminishes the fecundity and growth of worms. J Infect Dis. 2004 May 15; 189(10):1952-61.
    View in: PubMed
    Score: 0.052
  35. An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Sci Transl Med. 2022 Jan 26; 14(629):eabj5305.
    View in: PubMed
    Score: 0.045
  36. Safety and immunogenicity of a recombinant vaccine against Trypanosoma cruzi in Rhesus macaques. Vaccine. 2020 06 15; 38(29):4584-4591.
    View in: PubMed
    Score: 0.040
  37. Vaccines for hookworm infection. Pediatr Infect Dis J. 1997 Oct; 16(10):935-40.
    View in: PubMed
    Score: 0.033
  38. Genetic Adjuvantation of a Cell-Based Therapeutic Vaccine for Amelioration of Chagasic Cardiomyopathy. Infect Immun. 2017 09; 85(9).
    View in: PubMed
    Score: 0.033
  39. Vaccination of Gerbils with Bm-103 and Bm-RAL-2 Concurrently or as a Fusion Protein Confers Consistent and Improved Protection against Brugia malayi Infection. PLoS Negl Trop Dis. 2016 Apr; 10(4):e0004586.
    View in: PubMed
    Score: 0.030
  40. Advancing a vaccine to prevent human schistosomiasis. Vaccine. 2016 06 03; 34(26):2988-2991.
    View in: PubMed
    Score: 0.030
  41. Status of vaccine research and development of vaccines for leishmaniasis. Vaccine. 2016 06 03; 34(26):2992-2995.
    View in: PubMed
    Score: 0.030
  42. Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice. Vaccine. 2015 Aug 26; 33(36):4505-12.
    View in: PubMed
    Score: 0.028
  43. New tools for NTD vaccines: A case study of quality control assays for product development of the human hookworm vaccine Na-APR-1M74. Hum Vaccin Immunother. 2015; 11(5):1251-7.
    View in: PubMed
    Score: 0.027
  44. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccin Immunother. 2014; 10(3):648-58.
    View in: PubMed
    Score: 0.026
  45. Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. Expert Rev Vaccines. 2012 Sep; 11(9):1043-55.
    View in: PubMed
    Score: 0.023
  46. Enhanced protective efficacy of a chimeric form of the schistosomiasis vaccine antigen Sm-TSP-2. PLoS Negl Trop Dis. 2012; 6(3):e1564.
    View in: PubMed
    Score: 0.023
  47. Expression, immunogenicity, histopathology, and potency of a mosquito-based malaria transmission-blocking recombinant vaccine. Infect Immun. 2012 Apr; 80(4):1606-14.
    View in: PubMed
    Score: 0.022
  48. Neutralizing antibodies to the hookworm hemoglobinase Na-APR-1: implications for a multivalent vaccine against hookworm infection and schistosomiasis. J Infect Dis. 2010 May 15; 201(10):1561-9.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.